apitope.com Report : Visit Site

Technical data of the apitope.com

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host apitope.com. Currently, hosted in United Kingdom and its service provider is Linode LLC .

terrapinn.com 

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called nginx containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

home about about apitope leadership & senior management team board of directors clinical advisory board investors technology apitopes ® the apitope ® discovery platform autoimmune diseases pipeline pipeline multiple sclerosis graves’ disease uveitis other discovery programmes factor viii intolerance news news event schedule past events downloads ipo announcement contact us contact us locations partnering careers menu home about about apitope leadership & senior management team board of directors clinical advisory board investors technology apitopes ® the apitope ® discovery platform autoimmune diseases pipeline pipeline multiple sclerosis graves’ disease uveitis other discovery programmes factor viii intolerance news news event schedule past events downloads ipo announcement contact us contact us locations partnering careers apitope is a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapeutics targeting the immunological basis of autoimmune diseases. we use our novel, proprietary discovery platform to select and develop highly specific peptide-based therapies, known as “apitopes ® ”, which restore the natural balance of the immune system. this mechanism of action avoids global immune suppression and has the broad potential to treat a wide variety of autoimmune diseases. we have developed a robust pipeline of innovative, potential first-in-class product candidates in clinical and pre-clinical development, thereby focussing on autoimmune diseases with significant unmet medical need. find out more job opportunity scientist - click for more details location: bioville building, agoralaan a bis, 3590 diepenbeek – belgium contract: permanent, full time job function: we are seeking a highly motivated and creative scientist with in depth expertise in immunology/autoimmunity. the selected scientist will participate in or be responsible for the scientific progression of assigned technology or therapeutic areas. he/she carries out tasks in following areas: technical/experimental procedures, laboratory and equipment management, high level stock management and purchase procedures, general administration, quality system management. on a day to day basis the scientist will be part of a project team and will report to the chief research officer. main accountabilities: independently designs, plans, executes, analyses, interprets and reports scientific experiments manages internal & external research projects develops, evaluates, optimizes and implements new technologies, laboratory protocols and methodologies and increases productivity of the research group performs experimental trouble-shooting and proposes solutions writes and works according to standard operating procedures and work instructions skills requirements: phd degree in the area of biology, (bio) medicine, pharmacy or life sciences with focus on immunology/autoimmunity covering topics: t cell biology, t cell tolerance, in vitro cell biology, in vivo biology required technology skills base: facs, elispot, elisa and/or pcr/qpcr technologies cell culturing of human lymphocytes general skill requirements: felasa c accreditation quality management and documentation problem solving personal attributes communicates efficiently writing skills for both scientific papers and internal reports team player as the company working language is english, fluency in english in verbal and written form is required experience: a strong candidate will have a minimum of 3 years of post-doctoral experience or equivalent, preferably in a biotech industry setting. offer: we offer a stimulating scientific position within a high‐potential innovative biotech company. the scientist will have the opportunity to take part of an exciting scientific endeavor. he/she will be hired for a full-time position, for which an appropriate salary package is foreseen. the scientist will be based at bioville, life science incubator in diepenbeek, belgium. applications from suitable qualified candidates are invited to send their english cv to apitope at [email protected] quoting reference 2018/r&d001. for additional questions please contact lotta jansson +32 11 28 69 00. latest news apitope announces positive results with novel treatment for graves’ disease phase i data show early efficacy in the majority of patients and a very favourable safety profile hasselt, belgium, and chepstow, uk, 16 april 2018 – apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases (including multiple sclerosis (ms), graves’ disease and uveitis), today announced positive results from the phase i first in man clinical trial of its product candidate, atx-gd-59, in development for the treatment of graves’ disease. graves' disease is one of the most common autoimmune diseases with approximately 10 million patients across europe and the us and yet there have been no innovative treatments in more than 60 years. with graves’ disease, the immune system mistakenly attacks the thyroid gland and causes it to become overactive. symptoms can include an enlargement of the thyroid gland, swelling of the neck, localised abnormalities of skin, tremors, heat intolerance and sweating, significant weight loss, osteoporosis, atrial fibrillation and ocular changes in patients. each year 20-30 out of every 100,000 people are newly diagnosed with graves' disease. the ratio of women versus men diagnosed with graves' disease is 6:1 and around 2% of all women will develop graves' disease during their lifetime. dr simon pearce, professor of endocrinology, newcastle university, and chief investigator for the trial commenting on the results said: “it is very exciting to see these promising phase i results where atx-gd-59 has shown both an encouraging safety and tolerability profile as well as efficacy. with current first-line treatments having a high failure rate, and the second-line treatments being either invasive surgery or radioiodine, atx-gd-59 demonstrates the potential to address the high medical need for a new, safe and effective treatment for the neglected field of those suffering from graves' disease.” the phase i clinical study met the primary endpoint to assess the safety and tolerability of atx-gd-59 in 12 patients with graves’ disease. the majority of the per protocol subjects were either euthyroid, the clinical objective of therapy, or close to being euthyroid by the end of treatment; the effect was maintained during the 3 months follow up off therapy. importantly, tshr antibody levels were also reduced with close correlations between percentage decreases in antibody and thyroid hormone levels in line with the mechanism of action. dr keith martin, chief executive officer of apitope, commented: “we’re highly encouraged by these data as they provide further evidence that our apitope ® platform identifies safe and effective treatments for autoimmune diseases. these findings are important for graves’ disease patients in providing a potential new treatment paradigm aimed at the cause of the disease not just the symptoms. we will continue to progress the development of atx-gd-59 as a treatment for graves’ disease and are currently preparing to initiate a phase ii study in the first quarter of 2019.” the investigational product was administered intradermally (id) every two weeks over a period of 18 weeks in male and female patients that were not otherwise being treated with anti-thyroid therapy. following a titration period of 25, 50, 100, 400 and 800 μg in the initial eight weeks of treatment, a dose of 800 μg was administered fortnightly for an additional 10 weeks, comparable to the regime followed in the successful atx-ms-1467 multiple sclerosis (ms) trials. read more apitope announces publication of data in international peer-reviewed journal neurology on novel multiple sclerosis therapy hasselt, belgium, and chepstow, uk, 19 march 2018 – apitop

URL analysis for apitope.com

https://apitope.com/sitemap/
https://apitope.com/pipeline/
https://apitope.com/other-discovery-programmes/
https://apitope.com/apitope-announces-publication-of-data-in-international-peer-reviewed-journal-neurology-on-novel-multiple-sclerosis-therapy/
https://apitope.com/multiple-sclerosis/
https://apitope.com/clinical-advisory-board/
https://apitope.com/factor-viii-intolerance/
https://apitope.com/uveitis/
https://apitope.com/apitope-announces-positive-results-with-novel-treatment-for-graves-disease/
https://apitope.com/past-events/
https://apitope.com/board-directors/
https://apitope.com/downloads/
https://apitope.com/investors/
https://apitope.com/partnering/
https://apitope.com/background-auto-immunity/
nialtoservices.co.uk

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Domain Name: APITOPE.COM
Registry Domain ID: 287562291_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.register.it
Registrar URL: http://www.register.it
Updated Date: 2013-11-18T10:52:10Z
Creation Date: 2005-12-16T10:33:47Z
Registry Expiry Date: 2021-12-16T10:33:47Z
Registrar: Register.it SPA
Registrar IANA ID: 168
Registrar Abuse Contact Email: [email protected]
Registrar Abuse Contact Phone: +39.5520021555
Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited
Name Server: NS0.PHASE8.NET
Name Server: NS1.PHASE8.NET
Name Server: NS2.PHASE8.NET
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2017-09-25T11:04:31Z <<<

For more information on Whois status codes, please visit https://icann.org/epp

NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.

TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.

The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.

  REGISTRAR Register.it SPA

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =apitope.com

  PORT 43

  TYPE domain

DOMAIN

  NAME apitope.com

  CHANGED 2013-11-18

  CREATED 2005-12-16

STATUS
clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
clientTransferProhibited https://icann.org/epp#clientTransferProhibited
clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited

NSERVER

  NS0.PHASE8.NET 81.88.63.114

  NS1.PHASE8.NET 85.233.160.68

  NS2.PHASE8.NET 85.233.164.62

  REGISTERED yes

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .